ARC Therapies Advances Gut Microbiome Research with YB328 Toward Clinical Application

ARC Therapies Advances Gut Microbiome Research with YB328 Toward Clinical Application

Investigating Its Role as an Immune Adjuvant in Cancer Immunotherapy

ARC Therapies Advances Microbiome Research Toward Clinical Use

TOKYO, Aug. 20, 2025 /PRNewswire/ -- ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Center Japan, has initiated research of YB328, a newly identified gut microbe, toward clinical application. Utilizing its proprietary intellectual property, the company has designated the YB328 strain as ARC0812 (RUX: "Lux") and will proceed with preclinical and human clinical trials t…